AbbVie presents detailed Phase 1 data for ABBV-295 at EASD 2026
AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, describing favorable tolerability and a pharmacokinetic profile at EASD 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.